210 related articles for article (PubMed ID: 8528268)
1. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
2. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
3. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
8. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
9. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.
Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacoz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1995 Oct; 40(4):361-7. PubMed ID: 8554938
[TBL] [Abstract][Full Text] [Related]
10. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
[TBL] [Abstract][Full Text] [Related]
12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
[TBL] [Abstract][Full Text] [Related]
13. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
14. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
[TBL] [Abstract][Full Text] [Related]
15. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.
Steen VM; Molven A; Aarskog NK; Gulbrandsen AK
Hum Mol Genet; 1995 Dec; 4(12):2251-7. PubMed ID: 8634695
[TBL] [Abstract][Full Text] [Related]
16. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
[TBL] [Abstract][Full Text] [Related]
19. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.
Evans WE; Relling MV; Rahman A; McLeod HL; Scott EP; Lin JS
J Clin Invest; 1993 May; 91(5):2150-4. PubMed ID: 8098046
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
